[1] World Health Organization. Hepatitis B[Internet][2021-10-05]. https://www.who.int/news-room/fact-sheets/detail/hepatitis-b.
[2] 王贵强, 王福生, 庄辉, 等. 慢性乙型肝炎防治指南(2019年版). 中国病毒病杂志, 2020, 10(01): 1-25.
[3] Cui F, Shen L, Li L, et al. Prevention of chronic hepatitis B after 3 decades of escalating vaccination policy, China. Emerg Infect Dis, 2017, 23(5): 765-772.
[4] Byeon S, Cho JH, Jung HA, et al. PD-1 inhibitors for non-small cell lung cancer patients with special issues: Real-world evidence. Cancer Med, 2020, 9(7): 2352-2362.
[5] Burns EA, Muhsen IN, Anand K, et al. Hepatitis B virus reactivation in cancer patients treated with immune checkpoint inhibitors. J Immunother, 2021, 44(3): 132-139.
[6] Zhang X, Zhou Y, Chen C, et al. Hepatitis B virus reactivation in cancer patients with positive hepatitis B surface antigen undergoing PD-1 inhibition. J Immunother Cancer, 2019, 7(1): 322.
[7] Lake AC. Hepatitis B reactivation in a long-term nonprogressor due to nivolumab therapy. Aids, 2017, 31(15): 2115-2118.
[8] Pandey A, Ezemenari S, Liaukovich M, et al. A rare case of Pembrolizumab-induced reactivation of hepatitis B. Case Rep Oncol Med, 2018, 2018(5985131).
[9] Koksal AS, Toka B, Eminler AT, et al. HBV-related acute hepatitis due to immune checkpoint inhibitors in a patient with malignant melanoma. Annals of Oncology, 2017, 28(12): 3103-3104.
[10] Godbert B, Petitpain N, Lopez A, et al. Hepatitis B reactivation and immune check point inhibitors. Dig Liver Dis, 2021, 53(4): 452-455.
[11] Shah NJ, Al-Shbool G, Blackburn M, et al. Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection. J Immunother Cancer, 2019, 7(1): 353.
[12] Xu F, Zeng Z, Yan B, et al. Safety and efficacy of anti-PD-1 inhibitors in Chinese patients with advanced lung cancer and hepatitis B virus infection: a retrospective single-center study. Transl Lung Cancer Res, 2021, 10(4): 1819-1828.
[13] Pu D, Yin L, Zhou Y, et al. Safety and efficacy of immune checkpoint inhibitors in patients with HBV/HCV infection and advanced-stage cancer: A systematic review. Medicine (Baltimore), 2020, 99(5): e19013.
[14] 范文瀚. 合并HBV感染患者接受免疫抑制剂治疗后HBVr现状调查与风险因素分析.第二军医大学,2017.
[15] Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. J Hepatol, 2018, 67(4): 1560-1599.
[16] Okazaki T, Chikuma S, Iwai Y, et al. A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Nat Immunol, 2013, 14(12): 1212-1218.
[17] Keir ME, Butte MJ, Freeman GJ, et al. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol, 2008, 26(677-704).
[18] Schönrich G, Raftery MJ. The PD-1/PD-L1 axis and virus infections: A delicate balance. Front Cell Infect Microbiol. 2019 Jun 13;9:207. doi: 10.3389/fcimb.2019.00207. PMID: 31263684; PMCID: PMC6584848.
[19] Knolle PA, Thimme R. Hepatic immune regulation and its involvement in viral hepatitis infection. Gastroenterology, 2014, 146(5): 1193-1207.
[20] Peng GP, Li SP, Wu W, et al. PD-1 upregulation is associated with HBV specific T cell dysfunction in chronic hepatitis B patients. Mol Immunol, 2008, 45(4): 963-970.
[21] Pauken KE, Sammons MA, Odorizzi PM, et al. Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade. Science, 2016, 354(6316): 1160-1165.
[22] Dong Y, Li X, Zhang L, et al. CD4(+) T cell exhaustion revealed by high PD-1 and LAG-3 expression and the loss of helper T cell function in chronic hepatitis B. BMC Immunol, 2019, 20(1): 27.
[23] Cao H, Zhang R, Zhang W. CTLA4 interferes with the HBVspecific T cell immune response (Review). Int J Mol Med. 2018 Aug;42(2):703-712. doi: 10.3892/ijmm.2018.3688. Epub 2018 May 17. PMID: 29786112; PMCID: PMC6034931.
[24] Blank C, Mackensen A. Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. Cancer Immunol Immunother, 2007, 56(5): 739-745.
[25] Johnston RJ, Comps-Agrar L, Hackney J, et al. The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. Cancer Cell, 2014, 26(6): 923-937.
[26] Sakuishi K, Jayaraman P, Behar SM, et al. Emerging Tim-3 functions in antimicrobial and tumor immunity. Trends Immunol, 2011, 32(8): 345-349.
[27] Lang J, Neumann-Haefelin C, Thimme R. Immunological cure of HBV infection. Hepatol Int, 2019, 13(2): 113-124.
[28] El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet, 2017, 389(10088): 2492-2502.
[29] Lu S, Zhang L, Cheng Y, et al. P1.04-010 Checkmate 870: An open-label safety study of nivolumab in previously treated patients with non-small cell lung cancer in asia. J Thorac Oncol, 2017, 12(11):
[30] Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol, 2018, 19(7): 940-952.
[31] European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol, 2017, 67(2): 370-398.
[32] Reddy KR, Beavers KL, Hammond SP, et al. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015;148(1):215-219.
[33] Lau G, Yu ML, Wong G, et al. APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy. Hepatol Int, 2021, 15(5): 1031-1048.
[34] Wang Y, Han SB. Hepatitis B reactivation: A review of clinical guidelines. J Clin Gastroenterol, 2021, 55(5): 393-399. |
